StockNow
Calendar
Log in
U.S. Markets

Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone

StockNow breaking-news AI analysis

Merck and Moderna reported a 42% lower risk of recurrence or death versus Keytruda alone; OS data remain immature, and the safety profile was generally consistent with earlier combination studies.

News detail

Overall survival data are not yet mature, but favorable trend in OS with Intismeran plus Keytruda has been observed.

2 stocks
MRKMerck & Co., Inc.$149.23Current priceMRNAModerna, Inc. Common Stock$193.53Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US President Trump says "Iran is doing everything they can to drive up the price of Oil prior to the U.S. Midterm Election".

Fed

Money markets no longer fully price a Fed rate hike before end of 2026

Geopolitics

IDF and the US military have drawn up plans to renew joint strikes on Iran in the coming weeks, reports ABC citing sources